Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug

Dow Jones

Oct 06

By Connor Hart

Shares of Invivyd were higher after the company said the Food and Drug Administration cleared its investigational new drug application, as well as provided feedback to advance its drug that aims to prevent Covid.

The stock rose 13% to $1.31 in premarket trading Monday. Through Friday's close, shares have more than doubled so far this year.

Invivyd is developing VYD2311, a vaccine-alternative antibody to prevent Covid. The program will undergo testing, with separate studies set to compare the safety and efficacy of VYD2311 with placebo, as well as place VYD2311 in a head-to-head trial against an mRNA-based Covid vaccine.

The company said it intends to initiate these clinical trials as soon as practicable, aiming for the trails to start before the end of the year, with top-line data by mid-2026.

"We are moving as fast as possible to bring Americans a new choice in protection from Covid," Chairman Marc Elia said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

October 06, 2025 08:24 ET (12:24 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573672189"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573672189\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573672189?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573672189","market":"sh","top_or_hot":-1,"title":"Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Invivyd were higher after the company said the Food and Drug Administration cleared its investigational new drug application, as well as provided feedback to advance its drug that aims to prevent Covid. \n</p>\n<p>\n  The stock rose 13% to $1.31 in premarket trading Monday. Through Friday's close, shares have more than doubled so far this year. \n</p>\n<p>\n  Invivyd is developing VYD2311, a vaccine-alternative antibody to prevent Covid. The program will undergo testing, with separate studies set to compare the safety and efficacy of VYD2311 with placebo, as well as place VYD2311 in a head-to-head trial against an mRNA-based Covid vaccine. \n</p>\n<p>\n  The company said it intends to initiate these clinical trials as soon as practicable, aiming for the trails to start before the end of the year, with top-line data by mid-2026. \n</p>\n<p>\n  \"We are moving as fast as possible to bring Americans a new choice in protection from Covid,\" Chairman Marc Elia said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 08:24 ET (12:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvivyd Shares Climb After FDA Advances Its Covid-Preventing Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-06 20:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Invivyd were higher after the company said the Food and Drug Administration cleared its investigational new drug application, as well as provided feedback to advance its drug that aims to prevent Covid. \n</p>\n<p>\n  The stock rose 13% to $1.31 in premarket trading Monday. Through Friday's close, shares have more than doubled so far this year. \n</p>\n<p>\n  Invivyd is developing VYD2311, a vaccine-alternative antibody to prevent Covid. The program will undergo testing, with separate studies set to compare the safety and efficacy of VYD2311 with placebo, as well as place VYD2311 in a head-to-head trial against an mRNA-based Covid vaccine. \n</p>\n<p>\n  The company said it intends to initiate these clinical trials as soon as practicable, aiming for the trails to start before the end of the year, with top-line data by mid-2026. \n</p>\n<p>\n  \"We are moving as fast as possible to bring Americans a new choice in protection from Covid,\" Chairman Marc Elia said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 06, 2025 08:24 ET (12:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573672189","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573672189","pubTimestamp":1759753440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Invivyd were higher after the company said the Food and Drug Administration cleared its investigational new drug application, as well as provided feedback to advance its drug that aims to prevent Covid.The stock rose 13% to $1.31 in premarket trading Monday. Through Friday's close, shares have more than doubled so far this year.Invivyd is developing VYD2311, a vaccine-alternative antibody to prevent Covid. The program will undergo testing, with separate studies set to compare the safety and efficacy of VYD2311 with placebo, as well as place VYD2311 in a head-to-head trial against an mRNA-based Covid vaccine.The company said it intends to initiate these clinical trials as soon as practicable, aiming for the trails to start before the end of the year, with top-line data by mid-2026.\"We are moving as fast as possible to bring Americans a new choice in protection from Covid,\" Chairman Marc Elia said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IVVD":"Invivyd, Inc.","BK4539":"次新股"},"translate_title":"FDA推进其新冠预防药物后Invivyd股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVVD":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Invivyd were higher after the company said the Food and Drug Administration cleared its investigational new drug application, as well as provided feedback to advance its drug that aims to prevent Covid. \n\n\n  The stock rose 13% to $1.31 in premarket trading Monday. Through Friday's close, shares have more than doubled so far this year. \n\n\n  Invivyd is developing VYD2311, a vaccine-alternative antibody to prevent Covid. The program will undergo testing, with separate studies set to compare the safety and efficacy of VYD2311 with placebo, as well as place VYD2311 in a head-to-head trial against an mRNA-based Covid vaccine. \n\n\n  The company said it intends to initiate these clinical trials as soon as practicable, aiming for the trails to start before the end of the year, with top-line data by mid-2026. \n\n\n  \"We are moving as fast as possible to bring Americans a new choice in protection from Covid,\" Chairman Marc Elia said. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 06, 2025 08:24 ET (12:24 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}